Quick Answer
CervoMed Inc. reported Total Revenue of $4.01 million for fiscal year 2025.
CervoMed Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $4.01M -58.9% |
$9.74M +36.3% |
$7.14M | $0.00 | — | — |
| Net Income | -$26.97M -65.5% |
-$16.29M -650.1% |
-$2.17M +62.6% |
-$5.80M +75.9% |
-$24.10M -69.9% |
-$14.19M -20.2% |
| Diluted EPS | — | — | — | $2038891.00 +4.7% |
$1946859.00 -96.4% |
$53831973.00 +702.7% |
| Total Assets | $22.88M -46.9% |
$43.08M +332.0% |
$9.97M +139.9% |
$4.16M -89.0% |
$37.84M +36.5% |
$27.73M +15.0% |
| Cash and Equivalents | $8.24M -8.5% |
$9.00M +15.5% |
$7.79M +90.4% |
$4.09M -89.0% |
$37.31M +101.5% |
$18.52M +30.6% |
| Stockholders Equity | $18.22M -53.5% |
$39.20M +431.4% |
$7.38M +122.2% |
-$33.29M -195.3% |
$34.91M +40.7% |
$24.81M +23.2% |
| R&D Expense | $21.82M +16.1% |
$18.80M +122.8% |
$8.44M +531.4% |
$1.34M -84.3% |
$8.50M -9.8% |
$9.43M +42.4% |
| Operating Income | -$28.29M -55.2% |
-$18.23M -133.3% |
-$7.81M -124.8% |
-$3.48M +85.9% |
-$24.68M -54.5% |
-$15.97M -38.3% |
| Gross Profit | — | — | — | — | — | — |
| Shares Outstanding | 9.25M +6.3% |
8.70M +53.4% |
5.67M +995.1% |
518,140 -74.6% |
2.04M -96.8% |
64.02M +91.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $322.6K | -83.4% | -81.6% |
| Net Income | September 30, 2025 | -$7.73M | -62.5% | -23.5% |
| Diluted EPS | September 30, 2024 | -$0.55 | +21.4% | +21.4% |
| Total Assets | September 30, 2025 | $30.61M | -37.4% | -19.6% |
| Cash and Equivalents | September 30, 2025 | $9.44M | +21.9% | +13.4% |
| Stockholders Equity | September 30, 2025 | $26.01M | -43.0% | -22.2% |
| R&D Expense | September 30, 2025 | $6.04M | +17.9% | +18.2% |
| Operating Income | September 30, 2025 | -$8.04M | -49.1% | -21.6% |
| Gross Profit | March 31, 2014 | $0.00 | — | — |
| Shares Outstanding | September 30, 2025 | 9.25M | +12.1% | +0.0% |
- CervoMed Inc. reported Total Revenue of $4.01 million for fiscal year 2025.
- CervoMed Inc. showed a decrease of -58.9% in Total Revenue compared to the prior fiscal year.
- CervoMed Inc. reported Net Income of -$26.97 million for fiscal year 2025.
- CervoMed Inc. showed a decrease of -65.5% in Net Income compared to the prior fiscal year.
- CervoMed Inc. reported Diluted EPS of $2038891.00 per share for fiscal year 2022.
- CervoMed Inc. showed an increase of +4.7% in Diluted EPS compared to the prior fiscal year.
- CervoMed Inc. reported Total Assets of $22.88 million for fiscal year 2025.
- CervoMed Inc. showed a decrease of -46.9% in Total Assets compared to the prior fiscal year.
- CervoMed Inc. reported Cash and Equivalents of $8.24 million for fiscal year 2025.
- CervoMed Inc. showed a decrease of -8.5% in Cash and Equivalents compared to the prior fiscal year.
- CervoMed Inc. reported Stockholders Equity of $18.22 million for fiscal year 2025.
- CervoMed Inc. showed a decrease of -53.5% in Stockholders Equity compared to the prior fiscal year.
- CervoMed Inc. reported R&D Expense of $21.82 million for fiscal year 2025.
- CervoMed Inc. showed an increase of +16.1% in R&D Expense compared to the prior fiscal year.
- CervoMed Inc. reported Operating Income of -$28.29 million for fiscal year 2025.
- CervoMed Inc. showed a decrease of -55.2% in Operating Income compared to the prior fiscal year.
- CervoMed Inc. reported Gross Profit of -$1.74 million for fiscal year 2011.
- CervoMed Inc. showed a decrease of -921.2% in Gross Profit compared to the prior fiscal year.
- CervoMed Inc. reported Shares Outstanding of 9.25 million shares for fiscal year 2025.
- CervoMed Inc. showed an increase of +6.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: